Manchester United PLC vs Viatris Inc — how do they compare? Manchester United PLC trades at $22.8 (market cap $3.80B), while Viatris Inc trades at $16.23 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 4.9× Manchester United PLC's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| MANU | VTRS | |
|---|---|---|
Market Cap | $3.80B | $18.69B |
Sector | Media | Health |
52-Week High | $23.53 | $17.86 |
52-Week Low | $15.10 | $9.49 |
Enterprise Value | $4.74B | $30.80B |
Dividend Yield | 1.26% | 2.95% |
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $22.60, up 4.15% today, with a bearish technical signal. The company reported Q1 2026 EPS of $0.04, beating expectations, but missed in Q4 2025. Revenue trends show modest growth to $667M in 2025, though net income remains negative. Key developments include securing land for a new stadium and Champions League qualification boosting future revenue prospects.
The outlook is mixed; stadium development and cost reductions offer long-term upside, but persistent losses and high debt pose risks. Analysts are cautious with 40% buy ratings. Investment opportunity hinges on operational turnaround, while risks include weak cash flow and competitive pressures.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Trailing returns across standard periods
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →